logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Features of the liver condition at parients with a new COVID-19 infection

[Reviews]
Vadim Akhmedov; Galiya Bikbavova; Elena Khomutova;

COVID-19 or Coronavirus disease-19 is an acute infectious disease caused by the SARS-Cov-2 coronavirus (Severe Acute Respiratory Syndrome CoronaVirus 2). This review article highlights the most important extra-pulmonary possible consequences of a new viral infection, with the main focus on liver damage. Evaluation criteria are described – at the stages of treatment and in the early rehabilitation period in patients with COVID-19 according to the recent scientific articles.

Download

References:
1. Lai C. C., Shih T. P., Ko W. C., Tang H. J., Hsueh P. R. Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55(3):105924.
https://doi.org/10.1016/j.ijantimicag.2020.105924
2. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/ S0140-6736(20)30183-5
3. Al-Hajjar S., McIntosh K., Pediatric COVID-19: An update on the expanding pandemic. Int. J. Pediatr. Adolesc. Med. 2020;7(2):61-63.
https://doi.org/10.1016/j.ijpam.2020.05.001
4. Kannan S., Shaik Syed Ali P., Sheeza A., Hemalatha K. COVID-19 (Novel Coronavirus 2019) – recent trends. Eur. Rev. Med. Pharmacol. Sci. 2020;24(4):2006-2011.
https://doi.org/10.26355/eurrev_202002_20378
5. Shi H., Han X., Jiang N., Cao Y., Alwalid O. [et al.]. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet. Infect. Dis. 2020;20:425-434.
https://doi.org/10.1016/ S1473-3099(20)30086-4
6. Weston S., Frieman M. COVID-19: Knowns, Unknowns, and Questions. ASM Journal. 2020;18;5(2):e00203-20.
https://doi.org/10.1128/ mSphere.00203-20
7. Nikiforov V. V., Suranova T. G., Mironov A. Yu., Zabozlaev F. G. New coronavirus infection (COVID-19): etiology, epidemiology, clinic, diagnosis, treatment and prevention. Moscow, 2020. (In Russ.).
8. Prilutskiy A. S. Coronavirus disease 2019. Part 2: clinic, diagnosis, treatment, prevention. Vestnik gigiyeny i epidemiologii. – Bulletin of hygiene and epidemiology. 2020;24(1):87-101. (In Russ.).
9. Hosseiny M., Kooraki S., Gholamrezanezhad A., Reddy S., Myers L. Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome. Am. J. Roentgenol. 2020. 214(5):1078-1082.
https://doi.org/10.2214/AJR.20.22969
10. Wang D., Hu B., Hu C., Zhu F., Liu X. [et al.]. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069.
https://doi.org/10.1001/jama.2020.1585
11. Qi F., Qian S., Zhang S., Zhang Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem. Biophys. Res. Commun. 2020;526(1):135-140.
https://doi.org/10.1016/j.bbrc.2020.03.044
12. Wang F., Wang H., Fan J., Zhang Y., Wang H. [et al.]. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020;159(1):367-370.
https://doi.org/10.1053/j.gastro.2020.03.055
13. Fan Z., Chen L., Li J., Cheng X., Yang J. [et al.]. Cheng Clinical Features of COVID-19-Related Liver Functional Abnormality.Clin. Gastroenterol. Hepatol.2020;18(7):1561-1566.
https://doi.org/10.1016/j.cgh.2020.04.002
14. Zhang C., Shi L., Wang F. S. Liver injury in COVID 19: management and challenges. Lancet. Gastroenterol. Hepatol. 2020;5(5):428-430.
https://doi.org/10.1016/S2468-1253(20)30057-1
15. Li J., Fan J. G. Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease. J. Clin. Transl. Hepatol. 2020;8(1):13-17.
https://doi.org/0.14218/JCTH.2020.00019
16. Park S. E. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARSCoV-2; Coronavirus Disease-19). Clin. Exp. Pediatr. 2020;63(4):119-124.
https://doi.org/10.3345/cep.2020.00493
17. Liu W., Tao Z. W., Wang L., Yuan M. L., Liu K. [et al.]. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin. Med. J. (Engl.). 2020;133(9):1032-1038.
https://doi.org/10.1097/CM9.0000000000000775
18. Xu Z., Shi L., Wang Y., Zhang J., Huang L. [et al.]. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet. Respir. Med. 2020;8(4):420-422.
https://doi.org/10.1016/S2213-2600(20)30076-X
19. Mehta P., McAuley D. F., Brown M., Sanchez E., Tattersall R. S. [et al.]. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.
https://doi.org/10.1016/S0140-6736(20)30628-0
20. Liu J., Li S., Liu Ji., Liang B., Wang X., Wang H. [et al.]. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.
https://doi.org/10.1016/j.ebiom.2020.102763
21. Greenough T. C., Carville A., Coderre J., Somasundaran M., Sullivan J. L. [et al.]. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndromeassociated coronavirus. Am. J. Pathol. 2005;167:455-463.
https://doi.org/10.1016/S0002-9440(10)62989-6
22. Yeo C., Kaushal S., Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet. Gastroenterol. Hepatol. 2020;5:335-337.
https://doi.org/10.1016/S2468-1253(20)30048-0
23. Chau T. N., Lee K. C., Yao H., Tsang T. Y., Chow T. C. [et al.]. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004;39:302-310.
https://doi.org/10.1002/hep.20111
24. Tan Y. J., Fielding B. C., Goh P. Y., Shen S., Tan T. H. [et al.]. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J. Virol. 2004;78:14043-14047.
https://doi.org/10.1128/JVI.78.24.14043-14047.2004
25. Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. Liver Int. 2020;40(6):1278-1281.
https://doi.org/10.1111/liv.14470
26. Feng G., Zheng K. I., Yan Q. Q., Rios R. S., Targher G. [et al.]. COVID- 19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J. Clin. Transl. Hepatol. 2020;8:18-24.
https://doi.org/10.14218/JCTH.2020.00018
27. Yang X., Yu Y., Xu J., Shu H., Xia J. [et al.]. Clinical course and outcomes of critically ill patients with SARSCoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet. Respir. Med. 2020;8:475-481.
https://doi.org/10.1016/S2213-2600(20)30079-5
28. Cho J. Y., Kim S. S., Lee Y. S., Song D. S., Lee J. H. [et al.]. Management of liver diseases during the pandemic of coronavirus disease-19. Clin. Mol. Hepatol. 2020;26(3):243-250.
https://doi.org/10.3350/cmh.2020.0111
29. Gautret P., Lagier J. C., Parola P., Hoang V. T., Meddeb L. [et al.]. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020;56(1):105949.
https://doi.org/10.1016/j.ijantimicag.2020.105949
30. Ross S. B., Wilson M. G., Papillon-Ferland L., Elsayed S., Wu P. E. [et al.]. COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. J. Am. Geriatr. Soc. 2020;68(8):1636-1646.
https://doi.org/10.1111/jgs.16623
31. Chen J., Liu D., Liu L., Liu P., Xu Q. [et al.]. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Y. Zheyiang University (Medical Sci.) 2020;49(2):215-219.
https://doi.org/10.3785/j.issn.1008-9292.2020.03.03
32. Mocroft A., Lundgren J. D., Ross M., Fux C. A., Reiss P. [et al.]. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet. HIV. 2016;3(1):e23-32.
https://doi.org/10.1016/S2352-3018(15)00211-8
33. Thiim M., Friedman L. S. Hepatotoxicity of antibiotics and antifungals. Clin. Liver. Dis. 2003;7(2):381-399.
https://doi.org/10.1016/s1089-3261(03)00021-7
34. Lockwood A. M., Cole S., Rabinovich M. Azithromycininduced liver injury. Am. J. Health. Syst. Pharm. 2010;67(10):810-814.
https://doi.org/10.2146/ajhp080687
35. Podlasin R. B., Kowalska J. D., Pihowicz A., WojtychaKwaśnica B., Thompson M. [et al.]. How to follow-up a patient who received tocilizumab in severe COVID-19: a case report. Eur. J. Med. Res. 2020;25(1):37.
https://doi.org/10.1186/s40001-020-00438-x
36. Lu C. C., Chen M. Y., Lee W. S., Chang Y. L. Potential therapeutic agents against COVID-19: What we know so far. J. Chin. Med. Assoc. 2020;83(6):534-536.
https://doi.org/10.1097/JCMA.0000000000000318
37. Thachil J. The versatile heparin in COVID-19. J. Thromb. Haemost. 2020;18(5):1020-1022.
https://doi.org/10.1111/jth.14821
38. Maskin L. P., Olarte G. L., Palizas F. Jr., Velo A. E., Lurbet M. F. [et al.]. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):743.
https://doi.org/10.1186/s13063-020-04646-y
39. Xiang Z., Liu J., Shi D., Chen W., Li J. [et al.]. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int. J. Biol. Sci. 2020;16(13):2382-2391.
https://doi.org/10.7150/ijbs.47652
40. Kolditz M., Dellweg D., Geerdes-Fenge H., Lepper P. M., Schaberg T. [et al.]. Treatment with Dexamethasone in Patients with COVID-19 – A Position Paper of the German Respiratory Society (DGP). Pneumologie. 2020;74(8):493-495.
https://doi.org/10.1055/a-1216-5739
41. Itoh S., Igarashi M., Tsukada Y., Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta. Hepatogastroenterol. (Stuttg). 1977;24(6):415-418.
42. Hammond A., Ramersdorfer C., Palitzsch K. D., Schölmerich J., Lock G. Fatal liver failure after corticosteroid treatment of a hepatitis B virus carrier. Dtsch. Med. Wochenschr. 1999;124(22):687-690.
https://doi.org/10.1055/s-2007-1024398
43. Mantovani A., Beatrice G., Dalbeni A. Coronavirus dise ase 2019 and prevalence of chronic liver disease: metaanalysis. Liver. Int. 2020;40(6):1316-1320.
https://doi.org/10.1111/liv.14465
44. Kovalic A. J., Satapathy S. K., Thuluvath P. J. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol. Int. 2020;28:1-9.
https://doi.org/10.1007/s12072-020-10078-2
45. Medeiros A. K., Barbisan C. C., Cruz I. R., de Araújo E. M., Libânio B. B. [et al.]. Higher frequency of hepatic steatosis at CT among COVID-19-positive patients. Abdom. Radiol. (NY). 2020;45(9):2748-2754.
https://doi.org/10.1007/s00261-020-02648-7
46. Guler E., Unal N. G., Cinkooglu A., Savas R., Kose T. [et al.]. Correlation of liver-to-spleen ratio, lung CT scores, clinical, and laboratory findings of COVID-19 patients with two consecutive CT scans. Abdom. Radiol. 2021;46:1543-1551.
https://doi.org/10.1007/s00261-020-02805-y
47. Lei, P., Zhang L., Han P. Zheng C., Tong Q. [et al.]. Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury. Hepatol. Int. 2020;14:733-742.
https://doi.org/10.1007/s12072-020-10087-1
48. Medeiros A. K., Barbisan C. C., Cruz I. R. [et al.]. Higher frequency of hepatic steatosis at CT among COVID-19- positive patients. Abdom. Radio. 2020;45:2748-2754.
https://doi.org/10.1007/s00261-020-02648-7
49. Uchida Y., Uemura H., Yamaba S. [et al.]. Significance of liver dysfunction associated with decreased hepatic CT attenuation values in Japanese patients with severe COVID-19. J. Gastroenterol. 2020;55:1098-1106.
https://doi.org/10.1007/s00535-020-01717-4

Keywords: coronavirus, SARS-CoV-2, COVID-19, liver, dysfunction, treatment, complications


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy